Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.56
Bid: 1.56
Ask: 1.582
Change: -0.048 (-2.99%)
Spread: 0.022 (1.41%)
Open: 1.60
High: 1.60
Low: 1.56
Prev. Close: 1.608
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 May 2021 11:15

RNS Number : 0553A
Hemogenyx Pharmaceuticals PLC
27 May 2021
 

27 May 2021

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

TR-1 Standard form for notification of major holdings

 

Issuer Details

ISIN

GB00BYX3WZ24

Issuer Name

HEMOGENYX PHARMACEUTICALS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting

3. Details of person subject to the notification obligation

Name

Alexis Sandler

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

26-May-2021

6. Date on which Issuer notified

26-May-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.660000

0.000000

7.660000

75090685

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYX3WZ24

75090685

7.660000

Sub Total 8.A

75090685

7.660000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

 

13. Place Of Completion

London

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUBARRARUVUAR
Date   Source Headline
25th Apr 20247:00 amRNSFinal Results
28th Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSPlacing to Raise US$4.2 million
16th Feb 20247:00 amRNSCBR Brain Delivery
14th Feb 20247:00 amRNSCBR Intranasal Delivery
9th Feb 20247:00 amRNSFDA Consents to Phase I Trials of HEMO-CAR-T
2nd Feb 20247:00 amRNSApproval and Issuance of U.S. Conditioning Patent
16th Jan 20247:00 amRNSSubmission of Complete Response to Clinical Hold
8th Jan 20247:00 amRNSHEMO-CAR-T Process Qualification Run Completed
28th Nov 202312:19 pmRNSPlacing to Raise £534,375
27th Nov 20237:00 amRNSCBR Expanded to Treatment of Cancer
15th Nov 20237:00 amRNSLentivirus Re-manufacturing Completed
31st Oct 20237:00 amRNSTotal Voting Rights
28th Sep 202312:28 pmRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic Investment from Prevail Partners, LLC
14th Sep 20237:00 amRNSClinical Hold Lift Plan is accepted by FDA
8th Sep 20235:11 pmRNSCBR Patent Application Update
10th Jul 20237:00 amRNSFull FDA Review for HEMO-CAR-T IND
30th Jun 20234:07 pmRNSResult of Annual General Meeting
2nd Jun 20232:01 pmRNSPosting of Annual Report & Notice of AGM
2nd Jun 202311:24 amRNSClinical Hold on IND for HEMO-CAR-T
9th May 20237:00 amRNSSubmission of IND for HEMO-CAR-T
28th Apr 202310:05 amRNSEquity Incentive Pool Increase and Option Grant
28th Apr 20237:00 amRNSFinal Results for the Year Ended 31 December 2022
23rd Mar 20231:32 pmRNSHEMO-CAR-T Analytical Release Tests Completed
28th Feb 20237:00 amRNSTotal Voting Rights
7th Feb 20232:30 pmRNSAdmission of Shares to Official List
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSPlacing to Raise £4,056,250
23rd Jan 20237:00 amRNSHEMO-CAR-T 3rd Process Qualification Run Completed
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
12th Jan 20234:40 pmRNSSecond Price Monitoring Extn
12th Jan 20234:35 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
10th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSSingle CBR Can Treat Multiple Viruses
5th Jan 20234:40 pmRNSSecond Price Monitoring Extn
5th Jan 20234:35 pmRNSPrice Monitoring Extension
5th Jan 202311:05 amRNSSecond Price Monitoring Extn
5th Jan 202311:00 amRNSPrice Monitoring Extension
4th Jan 20237:00 amRNSHEMO-CAR-T Process Qualification Run Completed
12th Dec 20227:00 amRNSHEMO-CAR-T First PQ Run Completed
18th Nov 20223:19 pmRNSHEMO-CAR-T Process Development Runs Completed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.